Evaluation of a continuous glucose monitoring system compared with an in-house standard laboratory assay and a handheld point-of-care glucometer in critically ill neonatal foals

被引:15
|
作者
Hug, Sophie A. [1 ]
Riond, Barbara [2 ]
Schwarzwald, Colin C. [1 ]
机构
[1] Univ Zurich, Vetsuisse Fac, Equine Dept, CH-8057 Zurich, Switzerland
[2] Univ Zurich, Vetsuisse Fac, Clin Lab, CH-8057 Zurich, Switzerland
关键词
glucose metabolism; equine critical care; monitoring; BLOOD-GLUCOSE; REAL-TIME; ACCURACY; INSULIN; CATS; DOGS; SENSORS; HORSES;
D O I
10.1111/vec.12072
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Objective - To evaluate the applicability and accuracy of a continuous glucose monitoring system (CGMS) in critically ill foals by comparing the performance of the CGMS, a point-of-care (POC) glucometer, and an in-house standard laboratory assay (SLA). Design - Prospective study. Setting - University teaching hospital. Animals - Seven critically ill neonatal foals requiring intensive care. Interventions - Foals were instrumented with a CGMS that measured interstitial glucose concentration every 5 minutes for the duration of 15-79 hours. Capillary and venous blood samples were taken every 4-6 hours for POC and SLA measurements, respectively. Measurements and Main Results - Bland-Altman analysis showed a mean bias (95% limits of agreement) of -0.1 (-3.9 to 3.5) mmol/L for comparison of CGMS versus SLA, 0.06 (-3.9 to 4.0) mmol/L for comparison of CGMS versus POC glucometer, and -0.16 (-1.8 to 1.5) mmol/L for comparison of POC glucometer versus SLA. Percent agreement and weighted kappa for classification in hypoglycemia, normoglycemia, and hyperglycemia were 68.4% and 0.296 for CGMS versus SLA, 72.4% and 0.442 for CGMS versus POC glucometer, and 80.7% and 0.568 for POC glucometer versus SLA. Conclusions - The CGMS may be helpful for monitoring a trend in interstitial glucose concentration in critically ill neonatal foals. However, considering the wide limits of agreement between methods, the CGMS should only be used as an adjunctive device to other, more accurate and readily available methods that are able to detect acute changes in glucose concentration. Its use is further limited by the relatively high costs of the sensors, the mandatory 2-hour initialization period, and the difficulties of keeping the transducer in place in an active foal. The POC glucometer used in this study is easy to use and proved to be sufficiently accurate for repeated, stall-sided glucose monitoring in neonatal foals.
引用
收藏
页码:408 / 415
页数:8
相关论文
共 12 条
  • [1] Evaluation of the appropriateness of using a continuous glucose monitoring system and a point-of-care glucometer for measuring blood glucose in horses
    Grob, Anne J.
    Delarocque, Julien
    Feige, Karsten
    Warnken, Tobias
    PFERDEHEILKUNDE, 2024, 40 (02): : 115 - 128
  • [2] Continuous glucose monitoring system can improve the quality of glucose control and glucose variability compared with point-of-care measurement in critically ill patients A randomized controlled trial
    Lu, Meizhu
    Zuo, Yanyan
    Guo, Jun
    Wen, Xiaoping
    Kang, Yan
    MEDICINE, 2018, 97 (36)
  • [3] Performance Evaluation of a Glucose Monitoring System for Point-of-Care Testing With the Critically Ill Patient Population-A Multicenter Study
    Louie, Richard F.
    Curtis, Corbin M.
    Toffaletti, John G.
    Handel, Elizabeth A.
    Slingerland, Robbert J.
    Fokkert, Marion J.
    Muller, Wim
    Weinert, Sandra E.
    Lee, Debra M.
    Kotagiri, Sheela
    POINT OF CARE, 2015, 14 (01): : 37 - 41
  • [4] Insulin treatment guided by subcutaneous continuous glucose monitoring compared to frequent point-of-care measurement in critically ill patients: a randomized controlled trial
    Boom, Daphne T.
    Sechterberger, Marjolein K.
    Rijkenberg, Saskia
    Kreder, Susanne
    Bosman, Rob J.
    Wester, Jos P. J.
    van Stijn, Ilse
    DeVries, J. Hans
    van der Voort, Peter H. J.
    CRITICAL CARE, 2014, 18 (04):
  • [5] Insulin treatment guided by subcutaneous continuous glucose monitoring compared to frequent point-of-care measurement in critically ill patients: a randomized controlled trial
    Daphne T Boom
    Marjolein K Sechterberger
    Saskia Rijkenberg
    Susanne Kreder
    Rob J Bosman
    Jos PJ Wester
    Ilse van Stijn
    J Hans DeVries
    Peter HJ van der Voort
    Critical Care, 18
  • [6] THE SAFETY AND EFFICACY OF A SUBCUTANEOUS CONTINUOUS GLUCOSE MONITORING COMPARED TO POINT OF CARE MEASUREMENT IN CRITICALLY ILL PATIENTS: A RCT
    Boom, D. T.
    Rijkenberg, S.
    Kreder, S.
    Sechterberger, M. K.
    Bosman, R. J.
    van der Voort, P. H. J.
    INTENSIVE CARE MEDICINE, 2013, 39 : S362 - S362
  • [7] Evaluation of a hybrid protocol using continuous glucose monitoring and point-of-care testing in non-critically ill patients in a community hospital
    Baker, Matt
    Lauterwasser, Sara
    Valenti, Catherine
    Kallenberger, Michael
    Stolte, Haleigh
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2024, 81 (09) : e261 - e267
  • [8] The safety and efficacy of a subcutaneous continuous glucose monitoring system compared to point of care measurement in critically ill patients: a randomised controlled trial
    Boom, D. T.
    Rijkenberg, S.
    Kreder, S.
    Sechterberger, M. K.
    van der Voort, P. H. J.
    DIABETOLOGIA, 2013, 56 : S31 - S31
  • [9] Validation and feasibility of two Continuous Glucose Monitoring Systems (CGMS) against point-of-care AccuChek (R) in critically ill patients; a pilot study
    Westhoff, D.
    Bosman, R. J.
    Oudemans-van Straaten, H. M.
    DeVries, J. H.
    Wester, J.
    van Stijn, I.
    Zandstra, D. F.
    van der Voort, P. H. J.
    NETHERLANDS JOURNAL OF CRITICAL CARE, 2010, 14 (06): : 381 - 387
  • [10] Level of Agreement and Correlation Between the Estimated Hemoglobin A1c Results Derived by Continuous or Conventional Glucose Monitoring Systems Compared with the Point-of-Care or Laboratory-Based Measurements: An Observational Study
    Al Hayek, Ayman A.
    Sobki, Samia H.
    Al-Saeed, Abdulghani H.
    Alzahrani, Wael M.
    Al Dawish, Mohamed A.
    DIABETES THERAPY, 2022, 13 (05) : 953 - 967